28 results about "Platelet activation" patented technology

The utility model discloses a hemostasis assist device for vascular surgery, which relates to the technical field of medical instruments, and comprises a fixing mechanism, a vascular surgery hemostasis mechanism is arranged in the fixing mechanism, the vascular surgery hemostasis mechanism comprises a knob, and the bottom of the knob is fixedly connected with a threaded column. According to the hemostasis mechanism for the vascular surgery department, during hemostasis, the periphery of a wound can be heated through the heating block across the replacement pad, the temperature of the periphery of the wound reaches 37-42 DEG C, activation of platelets can be accelerated to a certain extent at the temperature, energy metabolism of the platelets is accelerated within the temperature range, and the blood circulation is accelerated. The increase of the concentration of calcium ions in the blood platelets is an important signal of platelet activation, and the increased concentration of the calcium ions can promote the activation of glycoprotein receptors on platelet membranes, so that the binding capacity of the blood platelets and fibrinogen is enhanced, the aggregation of the blood platelets is accelerated, and the hemostasis speed is accelerated.

Synthetic hemocompatible vascular grafts manufactured from polyvinyl alcohol-based biomaterials containing crystalline segments of polyvinyl alcohol, which are long-term fully functioning vascular grafts that provide no activity towards immune systems in recognizing surfaces as foreign bodies that would normally lead to fibrosis, platelet activation and subsequent thrombi formation, and thus occlusion of the grafts.

The application discloses a multifunctional blood vessel stent with a negative Poisson's ratio structure and a preparation method thereof, relates to the technical field of medical devices, and comprises the construction of a blood vessel stent model with a negative Poisson's ratio structure, selective laser melting additive manufacturing, chemical polishing treatment and surface biomimetic modification treatment. The stent can better adapt to the deformation of a blood vessel by virtue of the negative Poisson's ratio characteristic, reduces incompatibility caused by different deformation steps, the structure of the stent is round and smooth, blood flow turbulence and vortex at sharp corners of a traditional stent can be effectively avoided, the hemodynamic performance is improved, the risk of platelet activation and thrombosis is reduced, a surface gradient coating is prepared, multi-mechanism synergy is realized, and the formation of an endothelial layer on the surface of the stent is facilitated.

Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

The invention discloses application of a marker to preparation of a kit for diagnosing chronic obstructive pulmonary diseases. According to the application disclosed by the invention, the accuracy of diagnosing the chronic obstructive pulmonary disease by using (R)-3-hydroxytetradecanoic acid alone or in combination with the azelayl platelet activating factor is relatively high; on the basis of combination of (R)-3-hydroxytetradecanoic acid and an azelayl platelet activating factor, the compound is prepared. The compound can be further combined with one or two of 1-hexadecyl-2-(5-oxovaleryl)-sn-glycerol-3-phosphorylcholine, 1-O-hexadecyl-SN-glycerol-3-choline phosphoric acid, lauroyl-L-carnitine and beta-acetyl-gamma-O-alkyl-L-alpha-phosphatidylcholine to be used for diagnosing the chronic obstructive pulmonary disease. Therefore, a diagnostic kit for diagnosing the chronic obstructive pulmonary disease can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.

The invention discloses a macrophage-platelet targeting delivery system carrying genes and mitochondria as well as a preparation method and application of the macrophage-platelet targeting delivery system. The platelet loaded with the PPAR gamma gene nano-composite is covalently linked to the surface of macrophage through a click chemical reaction, and a novel cell composite carrier is constructed. According to the system, the natural chemotaxis of macrophages to an injured part is fully utilized to realize precise targeting, and PPAR gamma genes and functional mitochondria are synchronously released through platelet activation in an injured microenvironment, so that the energy metabolism and lipid homeostasis of the macrophages are cooperatively regulated and controlled, the cellular burial function of the macrophages is effectively recovered, and tissue repair and regeneration are promoted. Experimental results show that the delivery system is reliable in preparation method and high in targeting efficiency, axon regeneration, myelin sheath repair and motor function recovery can be remarkably promoted in a spinal cord injury model, and a brand-new synergistic treatment strategy is provided for tissue injury repair.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

This disclosure provides an antibody constructs that specifically bind CD9 with high affinity. These antibody constructs include a set of novel heavy chain and light chain complementarity determining regions (CDRs) sequences, optionally humanized variable regions, and engineered Fc region of the heavy chain constant region in order to eliminate undesirable platelet activation. The present invention also provides methods for diagnosing and treating conditions including cancer characterized by the aberrant expression of CD9 in the pertinent tissue and cells through the use of these anti-CD9 antibody constructs.

Multivalent anti-platelet glycoprotein I(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein I(b)alpha and lacking a Fc portion, therefore Bleeding Time do not interact with Fc receptor. The humanized antibodies are capable of preventing platelet activation and aggregation, and reducing thrombus size / growth and prevent vessel occlusion. They can be also very useful to decrease platelet-tumor cell interaction and decrease tumor metastasis. At therapeutic doses, the humanized antibodies lack the ability to induce platelet activation, induce thrombocytopenia; and / or prolong bleeding time.

This invention relates to the fields of biomedical engineering and regenerative medicine, and particularly to a plasma matrix composite membrane activated by autologous keratinized epithelial tissue fragments, its preparation method, and its applications. The composite membrane is obtained by mixing autologous keratinized epithelial tissue fragments with a liquid autologous plasma matrix in a specific ratio, utilizing tissue factors on the surface of the tissue fragments to trigger platelet activation, spontaneously forming a gel, and then pressing it into a membrane. This invention is the first to utilize the biointerface of autologous keratinized epithelial tissue fragments to activate platelets, eliminating the need for exogenous thrombin and achieving completely autologous in-situ gelation. The composite membrane formed after pressing possesses excellent mechanical properties and barrier function, and can be prepared in a single operation in the operating room without the need for in vitro cell culture. The composite membrane of this invention is used for oral soft tissue augmentation, such as widening of keratinized gingiva and alveolar ridge soft tissue augmentation, and has advantages such as no donor site damage, high biosafety, and ease of operation.

This invention discloses a platelet-rich plasma (PRP) preparation device, its preparation method, and its applications. The device comprises integrated sterile components for the entire process of blood collection, centrifugation, transfer, and recombination. Through an optimized secondary centrifugation process, it can stably and efficiently separate and enrich platelets from autologous whole blood, thereby preparing PRP that meets clinical requirements. The device features a rationally designed component structure and a standardized and simple operating procedure, effectively controlling unnecessary platelet activation during the preparation process and ensuring the bioactivity and release potential of growth factors in the PRP. Experimental results show that the growth factor enrichment efficiency and platelet activation level of the PRP obtained using this device are comparable to mainstream commercially available products, with superior ease of operation and standardization. This product provides a reliable and efficient PRP preparation tool for clinical use, particularly suitable for adjunctive treatment of trauma repair such as fracture surgery.

A container, e.g., a bag, for processing whole blood or a whole blood component and a system for processing whole blood or a whole blood component including the container. The container includes a body and an interior chamber. The body has a bulk portion and a surface portion defining an interior surface of the body. The bulk portion of the body is formed from a polymeric composition comprising a thermoplastic polymer. The surface portion of the body includes a biocompatible material that reduces platelet activation, platelet aggregation, or adhesion of platelets to the interior surface of the body. The interior chamber is at least partially defined by the interior surface of the body.

The application belongs to the field of medical biotechnology, and particularly relates to a method for in-vitro ADP stimulation determination of platelet activation and application. The method provided by the application comprises: S1, adding buffer solution, ADP solution and anticoagulant whole blood sample into a homologous control tube and a to-be-detected tube respectively; S2, placing the homologous control tube and the to-be-detected tube at 18-28 DEG C for 5-30 min for stimulation; the final concentration of the ADP solution in the step S1 is 5-160 micromol / L; and the addition amount of the anticoagulant whole blood sample is 5-10 microliters. The method provided by the application is more direct and simple to operate, and only needs to be completed at normal temperature. After the stimulation is completed, the antibody reagent is directly added without the need of taking a flow tube for secondary dispensing and adding the antibody reagent. In addition, the sample amount of the method provided by the application is significantly reduced, the burden of patients is reduced, the ADP amount is greatly reduced, the reagent amount is saved, the collection time is significantly shortened, and the detection efficiency is greatly improved.

The application discloses an anti-platelet GPIb-IX antibody and application thereof, and belongs to the technical field of biological medicines. The application selects the starting signal protein GPIb-IX of arterial thrombosis as a target, and prepares an anti-human GPIb-IX humanized antibody. Specifically, human platelets are used as antigens to immunize mice, and a mouse-derived anti-human GPIb-IX antibody is obtained through screening and preparation, a humanized anti-GPIb-IX antibody ATHA is constructed by mutating a human-derived sequence, the heavy chain variable region of the ATHA comprises a VH-CDR3 shown in SEQ ID NO. 1, and the light chain variable region comprises a VL-CDR3 shown in SEQ ID NO. 2. The Fab segment of the ATHA can effectively inhibit platelet activation mediated by the GPIb-IX receptor, inhibit thrombosis in the body without accompanying side effects such as platelet reduction and bleeding, and has the characteristics of high specificity, good safety and small side effects. Meanwhile, the ATHA can remove platelets. Therefore, the ATHA-Fab has clinical value as a new anti-thrombotic drug, and can be used for treating diseases related to arterial thrombosis. The ATHA can remove platelets, and can be used for treating diseases with increased platelet quantity or removing platelets in the body.

The invention discloses application of a platelet activating factor in preparation of a medicine for treating endometrial cancer. Cell experiments and animal in-vivo experiments prove that the platelet activating factor can effectively inhibit proliferation of the endometrial cancer and inhibit in-vivo growth of the endometrial cancer, the targeted binding effect of PAF and ATF3 is clarified, a new method is provided for treatment of the endometrial cancer, and the platelet activating factor is expected to be applied to preparation of drugs for inhibiting proliferation of the endometrial cancer and has a wide application prospect. The invention has important significance for clinical treatment of endometrial cancer.

This invention relates to the field of biomedical detection technology, specifically a method for detecting platelet-rich plasma based on biosensors. The method includes: preparing a biosensor interface capable of recognizing platelet surface-specific antigens; applying the sample to be tested to the interface for a specific binding reaction; monitoring signal changes during the reaction process in real time and acquiring raw data; preprocessing the data to obtain a purification response curve; extracting characteristic parameters such as binding rate, equilibrium response value, and dissociation rate constant from the curve; and finally, analyzing the above parameters based on a pre-established quantitative relationship model to simultaneously calculate the platelet concentration and platelet activation index of the sample. This method achieves simultaneous, rapid, and integrated quantitative assessment of platelet quantity and functional activity in platelet-rich plasma.

The present disclosure relates to the field of biomedical technology, and specifically relates to a reagent combination, kit and detection method for detecting platelet activation marker PAC-1. The reagent combination comprises: a first detection probe, a second detection probe, a third detection probe and a fourth detection probe; the first detection probe is formed by at least conjugating a DNA1 and a PAC-1 antibody 1; the second detection probe is formed by at least conjugating a PAC-1 antibody 2 and a DNA2; the third detection probe is a DNA3 labeled with a fluorescent molecule; the fourth detection probe is an antioxidant bound to a carrier molecule. When the reagent combination or kit of the present disclosure is used to detect PAC-1, the cost is relatively low and whole blood can be used for detection, which allows for convenience and speed while avoiding artificial platelet activation in in vitro samples; moreover, the detection operation procedure is simple and the overall detection time is relatively short, making the invention suitable for the actual needs of clinical detection of PAC-1.

An implantable pump system is provided, including an implantable blood pump suitable for use as a partial support assist device, the system further including an extracorporeal battery and a controller coupled to the implantable pump, and a programmer selectively periodically coupled to the controller to configure and adjust operating parameters of the implantable pump. The implantable pump includes a flexible membrane coupled to an electromagnetic actuator including a magnetic assembly and electromagnetic assembly, so that when the electromagnetic assembly is energized, the electromagnetic assembly causes wavelike undulations to propagate along the flexible membrane to propel blood through the implantable pump. The controller may be programmed by a programmer to operate at frequencies and duty cycles that mimic physiologic flow rates and pulsatility while operating in an efficient manner that avoids thrombus formation, hemolysis and / or platelet activation.

The invention discloses application of phytosphingosine in preparation of a platelet activator, a platelet activation method and a platelet function detection kit, in particular to a method based on PHS accumulation and platelet activation, and solves the problems of low efficiency and weak pathological correlation of an exogenous activator. In addition, the invention also discloses a main application scene of applying the PHS to platelet activation, which covers preparation of a platelet activator, in-vitro platelet function detection, MPN disease model construction and antithrombotic drug screening.

This invention relates to the use of hydroxysaffron yellow A in the treatment of platelet-related diseases. Specifically, this invention provides a use of hydroxysaffron yellow A for preparing compositions for the prevention and / or treatment of platelet-related diseases. This invention discovers that hydroxysaffron yellow A can reduce platelet count and the ratio of large platelets, as well as inhibit platelet aggregation and agglutination, for the prevention and treatment of diseases associated with elevated platelet counts such as thrombocytosis, diseases associated with elevated large platelet ratios, and diseases associated with platelet activation, thereby preventing and treating platelet-related diseases.

The invention discloses a multifunctional intravascular stent with a negative Poisson's ratio structure and a preparation method of the multifunctional intravascular stent, and relates to the technical field of medical instruments, and the preparation method comprises construction of an intravascular stent model with the negative Poisson's ratio structure, selective laser melting additive manufacturing, chemical polishing treatment and surface bionic modification treatment. The stent can better adapt to deformation of blood vessels by utilizing the negative Poisson's ratio characteristic, reduces incompatibility caused by desynchrony of deformation, is round and smooth in structure, can effectively avoid blood flow turbulence and vortex which are easily generated at sharp corners of a traditional stent, improves hemodynamic performance, reduces risks of platelet activation and thrombosis, and has good application prospects. By preparing the surface gradient coating, multi-mechanism synergy is realized, and the formation of the endodermis on the surface of the stent is facilitated.

The invention relates to the technical field of biomedicine detection, in particular to a platelet-rich plasma detection method based on a biosensor, which comprises the following steps: preparing a biosensing interface with a recognition function on platelet surface specific antigens; a sample to be detected is applied to the interface for a specific binding reaction; monitoring signal change in the reaction process in real time and acquiring original data; preprocessing the data to obtain a purification response curve; extracting characteristic parameters such as a binding rate, a balance response value and a dissociation rate constant; and finally, based on a pre-established quantitative relation model, analyzing the parameters, and synchronously calculating the platelet concentration value and the platelet activation index of the sample. According to the method, synchronous, rapid and integrated quantitative evaluation on the quantity and functional activity of platelets in the platelet-rich plasma is realized.

The invention relates to the technical field of medicines, in particular to application of uric acid in preparation of a medicine for treating liver injury and a medicine for inhibiting platelets during liver injury. The invention relates to an application of uric acid in the aspects of treating liver injury and inhibiting platelet activation, which indicates that uric acid (especially exogenous uric acid) can be used for preparing the medicines for treating liver injury and platelet activation, and provides technical enlightenment for preparing the medicines for treating liver injury and liver cirrhosis hypercoagulable state. The invention discloses that exogenous uric acid has a treatment effect on acute liver injury induced by thioacetamide (TAA). The exogenous uric acid has a treatment effect on chronic liver injury caused by cholestasis. The mechanism is related to reduction of oxidative stress and inflammatory response and further reduction of cell senescence. The condition of a liver cirrhosis patient is related to the platelet activation state, exogenous uric acid inhibits TAA and platelet activation in a common bile duct ligation (BDL) rat model, and it is prompted that the liver disease and the liver cirrhosis hypercoagulable state can be treated.

The present invention provides engineered platelets having a chimeric platelet receptor (CPR) with desired target specificity. Furthermore, the engineered platelets may contain cargo that can be released upon platelet activation. In addition, the platelets can be generated in vitro from megakaryocytes engineered to produce non-thrombotic platelets. [Solution] To provide an engineered megakaryocyte or precursor capable of reducing thrombogenic ability and / or producing platelets with reduced thrombogenic ability, comprising the disruption or deletion of at least one gene encoding a protein involved in the recognition of a primary stimulus for thrombosis, one gene encoding a protein involved in the recognition of a secondary mediator for thrombosis, and one gene encoding a protein involved in the release of a secondary mediator for thrombosis.

In an illustrative embodiment, methods and system for increasing coagulation potential and / or triggering a higher platelet activation rate in a subject via auricular neurostimulation include contacting skin of the subject with one or more therapeutic electrodes, each electrode positioned in a respective region of nerve structures of the auriculotemporal nerve (ATN), nerve structures connected to the ATN, nerve structures of the auricular branch of the vagus nerve (ABVN), or nerve structures connected to the ABVN, applying, to the electrodes, one or more stimulation patterns.

Biochemical markers that can be measured to determine the level of mechanical activation of a population of platelets are provided, and their use to prepare molecular signatures thereof are provided. The markers include phosphatidylserine, thrombin, integrin GPIIb / IIIa activation, glycoprotein GP Ib, P-selectin; platelet size; microparticle generation, or lipidomic profile of the membrane. The disclosed markers, measurement thereof, and signatures composed therefrom can be used in a variety of methods of patient selection, treatment monitoring, treatment selection, including both devices and active agents, and methods of treating subjects in need thereof, particularly humans. Examples of such methods include, but are not limited to, reducing shear-activated platelets; selecting a blood-contacting medical device; selecting between two or more medical devices; identifying a subject at a risk of developing a thrombogenic event; monitoring the prophylactic treatment of a subject; selecting a mechanoceutical agent; and delivering an agent to a subject.

A container, e.g., a bag, for processing whole blood or a whole blood component and a system for processing whole blood or a whole blood component including the container. The container includes a body and an interior chamber. The body has a bulk portion and a surface portion defining an interior surface of the body. The bulk portion of the body is formed from a polymeric composition comprising a thermoplastic polymer. The surface portion of the body includes a biocompatible material that reduces platelet activation, platelet aggregation, or adhesion of platelets to the interior surface of the body. The interior chamber is at least partially defined by the interior surface of the body.